natgillin/translations-raw huggingface dataset:
With an updated follow-up at a median of 10 years, long term comparison of the treatment effects of Arimidex relative to tamoxifen were shown to be consistent with previous analyses. 
Ob posodobljenem spremljanju po mediano 10 letih je dolgoročna primerjava učinkov zdravljenja z zdravilom Arimidex v primerjavi s tamoksifenom pokazala rezultate, skladne s prejšnjimi analizami.
This treatment arm was discontinued from the study. 
Ta terapevtski krak je bil v študiji opuščen.
McCune-Albright Syndrome study 
Študija McCune-Albrightovega sindroma
• Carpal tunnel syndrome (tingling, pain, coldness, weakness in parts of the hand). 
• sindrom zapestnega kanala (mravljinčenje, bolečine, hlad, šibkost v delih dlani)
This is because Arimidex can affect the way some medicines work and some medicines can have an effect on Arimidex. 
Zdravilo Arimidex namreč lahko vpliva na delovanje nekaterih zdravil in nekatera zdravila lahko vplivajo na zdravilo Arimidex.
There are no data to support the use of Arimidex with LHRH analogues. 
Ni podatkov, ki bi podpirali uporabo zdravila Arimidex z analogi LHRH.
The primary objective was to evaluate the safety and efficacy of Arimidex 1 mg/day in patients with MAS. 
Primarni cilj je bila ocena varnosti in učinkovitosti zdravila Arimidex v odmerku 1 mg/dan pri bolnicah z MAS.
Triazole, the major metabolite in plasma, does not inhibit aromatase. 
Triazol, glavni presnovek v plazmi, ne zavira aromataze.
*** Vaginal bleeding has been reported commonly, mainly in patients with advanced breast cancer during the first few weeks after changing from existing hormonal therapy to treatment with Arimidex. 
*** Pogosto je bila opisana krvavitev iz nožnice, predvsem pri bolnicah z napredovalim rakom dojke v prvih nekaj tednih po prehodu z obstoječega hormonskega zdravljenja na zdravljenje z zdravilom Arimidex.
No data on the potential long-term effects of Arimidex treatment in children and adolescents are available (see also section 5.3). 
Podatkov o morebitnih dolgoročnih učinkih zdravljenja z zdravilom Arimidex pri otrocih in mladostnikih ni (glejte tudi poglavje 5.3).
• Feeling weak. 
• občutek šibkosti
• Skin rash caused by hypersensitivity (this can be from allergic or anaphylactoid reaction). 
• izpuščaj na koži, ki ga povzroči preobčutljivost (ta je lahko zaradi alergijske ali anafilaktoidne reakcije)
Anastrozole is eliminated slowly with a plasma elimination half-life of 40 to 50 hours. 
Anastrozol se odstrani počasi; plazemski eliminacijski razpolovni čas je od 40 do 50 ur.
Absorption of anastrozole is rapid and maximum plasma concentrations typically occur within two hours of dosing (under fasted conditions). 
Absorpcija anastrozola je hitra in največja koncentracija v plazmi je praviloma dosežena v dveh urah po uporabi (na tešče).
Use in children Arimidex should not be given to children and adolescents. 
Uporaba pri otrocih Zdravila Arimidex se ne sme dajati otrokom in mladostnikom.
It may harm them, even if their symptoms are the same as yours. 
čeprav imajo znake bolezni, podobne vašim.
Arimidex contains a substance called anastrozole. 
Zdravilo Arimidex vsebuje snov, imenovano anastrozol.
There was no significant difference in growth rate after 12 months of treatment, relative to the growth rate during the 6 months prior to entering the study. 
Po 12 mesecih zdravljenja ni bilo nobene značilne razlike v hitrosti rasti glede na hitrost rasti v 6 mesecih pred vstopom v študijo.
Stevens-Johnson syndrome Angioedema 
Stevens-Johnsonov sindrom angioedem
Ischaemic cerebrovascular events Endometrial cancer 
Ishemični cerebrovaskularni dogodki Rak endometrija
Tell your doctor or pharmacist if you are taking the following: - A medicine known as an ‘LHRH analogue'. 
Zdravniku ali farmacevtu morate povedati, če jemljete katero od naslednjih zdravil: - Zdravilo, imenovano "analog LHRH".
These changes occurred at a dose which represents 100-fold greater exposure than occurs at human therapeutic doses, and are considered not to be clinically relevant to the treatment of patients with anastrozole. 
Te spremembe so se pojavile v odmerku, ki predstavlja 100-krat večjo izpostavljenost, kot je dosežena s terapevtskimi odmerki za človeka, in ne veljajo za klinično pomembne pri zdravljenju bolnikov z anastrozolom.
Those effects that were seen (placental enlargement in rats and pregnancy failure in rabbits) were related to the pharmacology of the compound. 
Opaženi učinki (povečanje placente pri podganah in neuspeh brejosti pri kunkah) so bili povezani s farmakologijo spojine.
• Allergic (hypersensitivity) reactions including face, lips, or tongue. 
• alergijske (preobčutljivostne) reakcije, ki zajamejo obraz, ustnice ali jezik.
Table 4 ABCSG 8 trial endpoint and results summary Efficacy endpoints 
Preglednica 4 Povzetek končnih točk in rezultatov preskušanja ABCSG 8 Končne točke učinkovitosti
If you take more Arimidex than you should If you take more Arimidex than you should, talk to a doctor straight away. 
Če ste vzeli večji odmerek zdravila Arimidex, kot bi smeli Če ste vzeli večji odmerek zdravila Arimidex, kot bi smeli, se takoj posvetujte z zdravnikom.
In the pivotal clinical trial, efficacy was not demonstrated and safety was not established (see section 5.1). 
V ključnem kliničnem preskušanju učinkovitost ni bila dokazana in varnost ni bila ugotovljena (glejte poglavje 5.1).
It does this by blocking a natural substance (an enzyme) in your body called ‘aromatase'. 
To doseže z blokado naravne telesne snovi (encima), imenovane "aromataza".
Anastrozole is only 40% bound to plasma proteins. 
Zdravilo Arimidex je 40 % vezano na beljakovine v plazmi.
‘Stevens-Johnson syndrome'. 
To je znano kot "Stevens-Johnsonov sindrom".
Women with osteoporosis or at risk of osteoporosis, should have their bone mineral density formally assessed at the commencement of treatment and at regular intervals thereafter. 
Ženske z osteoporozo ali tveganjem zanjo morajo na začetku zdravljenja in pozneje v rednih presledkih opraviti formalno oceno mineralne gostote kosti.
White, round, biconvex tablet with logo on one side and strength on the other. 
Bela, okrogla bikonveksna tableta z logom na eni strani in jakostjo na drugi.
These effects were related to the pharmacology of the compound and were completely reversed after a 5-week compound withdrawal period. 
Ti učinki so bili povezani s farmakologijo spojine in so popolnoma izginili 5 tednov po odtegnitvi spojine.
Do not take Arimidex if you are pregnant or breast-feeding. 
Ne jemljite zdravila Arimidex, če ste noseči ali dojite.
What Arimidex is and what it is used for Before you take Arimidex How to take Arimidex Possible side effects 
Kaj je zdravilo Arimidex in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Arimidex Kako jemati zdravilo Arimidex Možni neželeni učinki
Anastrozole in girls was widely distributed and slowly eliminated. 
Anastrozol se je pri deklicah porazdelil širše in se je odstranil počasneje.
Arimidex is a potent and highly selective non-steroidal aromatase inhibitor. 
Arimidex je močan in zelo selektiven nesteroiden zaviralec aromataze.
Your doctor will manage these risks according to treatment guidelines for managing bone health in women who have gone through the menopause. 
Zdravnik bo obvladal ta tveganja v skladu s smernicami za zagotavljanje zdravja kosti pri ženskah, ki so že imele menopavzo.
Arimidex should be taken orally. 
Zdravilo Arimidex je treba jemati peroralno.
The European Medicines Agency has waived the obligation to submit the results of studies with Arimidex in one or several subsets of the paediatric population in short stature due to growth hormone deficiency (GHD), testotoxicosis, gynaecomastia, and McCune-Albright syndrome (see section 4.2). 
Evropska agencija za zdravila je odstopila od obveznosti po predložitvi rezultatov študij zdravila Arimidex pri eni ali več podskupinah pediatrične populacije z nizko rastjo zaradi pomanjkanja rastnega hormona, testotoksikozo, ginekomastijo in McCune-Albrightovim sindromom (glejte poglavje 4.2).
If you go into the hospital, let the medical staff know you are taking Arimidex. 
Če greste v bolnišnico, morate zdravstvenemu osebju povedati, da jemljete zdravilo Arimidex.
WHAT ARIMIDEX IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO ARIMIDEX IN ZA KAJ GA UPORABLJAMO
Daily doses of Arimidex up to 10 mg do not have any effect on cortisol or aldosterone secretion, measured before or after standard adrenocorticotrophic hormone (ACTH) challenge testing. 
Dnevni odmerki zdravila Arimidex do 10 mg ne vplivajo na izločanje kortizola ali aldosterona, merjeno pred ali po standardnem provokacijskem testiranju z adrenokortikotropnim hormonom (ACTH).
Do not take Arimidex if you are already taking any of the following medicines: - Certain medicines used to treat breast cancer (selective estrogen receptor modulators), e.g., medicines that contain tamoxifen. 
Ne jemljite zdravila Arimidex, če že jemljete katero od naslednjih zdravil: - Določena zdravila za zdravljenje raka dojke (selektivni modulatorji estrogenskih receptorjev), npr.
However, asthenia and somnolence have been reported with the use of Arimidex and caution should be observed when driving or operating machinery while such symptoms persist. 
Vendar sta bili med uporabo zdravila Arimidex opisani astenija in zaspanost, zato je pri vožnji in upravljanju strojev potrebna previdnost, dokler trajajo takšni simptomi.
The effects of Arimidex on fertility in humans have not been studied. 
Vplivi zdravila Arimidex na plodnost pri človeku niso raziskani.
- The usual dose is one tablet once a day. 
- Običajen odmerek je ena tableta enkrat na dan. - Tableto po možnosti vzemite vsak dan ob istem času.
The reduction was transient as all mating and fertility parameters were similar to control group values following a 9 week treatment-free recovery period. 
Zmanjšanje je bilo prehodno, ker so bile po 9 tednih brez uporabe zdravila vrednosti vseh parametrov parjenja in plodnosti podobne kot v kontrolni skupini.
Number of events (frequency) Arimidex (N=1,297) 
Število dogodkov (pogostnost) Arimidex (n = 1.297)
0.70 to 1.00 
0,70 do 1,00
Cutaneous vasculitis (including some reports of Henoch-Schönlein purpura)** 
Redki multiformni eritem anafilaktoidna reakcija kožni vaskulitis (vključno z nekaterimi primeri Henoch-Schönleinove purpure)**
Arimidex has no or negligible influence on the ability to drive and use machines. 
Zdravilo Arimidex nima ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja s stroji.
The combination of Arimidex and tamoxifen did not demonstrate any efficacy benefits in comparison with tamoxifen in all patients as well as in the hormone receptor-positive population. 
Kombinacija zdravila Arimidex in tamoksifena ni pokazala koristi glede učinkovitosti v primerjavi s tamoksifenom ne pri vseh bolnicah ne v populaciji s pozitivnimi hormonskimi receptorji.
Anastrozole is extensively metabolised by postmenopausal women with less than 10% of the dose excreted in the urine unchanged within 72 hours of dosing. 
Anastrozol se pri ženskah po menopavzi izdatno presnovi in manj kot 10 % odmerka se nespremenjenega izloči v urinu v 72 urah po uporabi.
Dialysis may be helpful because Arimidex is not highly protein bound. 
Dializa morda lahko koristi, ker zdravilo Arimidex ni v veliki meri vezano na beljakovine.
In postmenopausal women, estradiol is produced primarily from the conversion of androstenedione to estrone through the aromatase enzyme complex in peripheral tissues. 
Pri ženskah po menopavzi nastaja estradiol predvsem s pretvorbo androstendiona v estron, ki poteka s kompleksom encima aromataze v perifernih tkivih.
There were no adverse effects on behaviour or reproductive performance of the first generation offspring attributable to maternal treatment with anastrozole. 
V prvi generaciji potomstva ni bilo neželenih učinkov na vedenje ali reproduktivno sposobnost, ki bi jih bilo mogoče pripisati materinemu prejemanju anastrozola.
Study 1033IL/0027 showed that Arimidex and tamoxifen had similar objective tumour response rates and time to tumour progression. 
Študija 1033IL/0027 je pokazala, da sta zdravilo Arimidex in tamoksifen dosegla podoben delež objektivnega odziva tumorja in časa do napredovanja tumorja.
However, some people may occasionally feel weak or sleepy while taking Arimidex. 
A nekaterim osebam se med jemanjem zdravila Arimidex občasno lahko pojavi šibkost ali zaspanost.
If you stop taking Arimidex Do not stop taking your tablets unless your doctor tells you to. 
Če ste prenehali jemati zdravilo Arimidex Ne nehajte jemati teh tablet, če vam tega ne naroči zdravnik.
• Patients with known hypersensitivity to anastrozole or to any of the excipients as referenced in section 6.1. 
• bolnicah z znano preobčutljivostjo za anastrozol ali katerokoli pomožno snov v zdravilu (pomožne snovi so navedene v poglavju 6.1).
• Allergic (hypersensitivity) reactions with swelling of the throat that may cause difficulty in swallowing or breathing. 
• alergijske (preobčutljivostne) reakcije z otekanjem žrela, ki lahko povzroči težave s požiranjem ali dihanjem.
The secondary objectives were to evaluate the proportion of patients with reductions from baseline in the calculated volume of gynaecomastia of both breasts combined of at least 50% between day 1 and after 6 months of study treatment, and patient tolerability and safety. 
Sekundarni cilji so bili ocena deleža bolnikov z zmanjšanjem izračunanega volumna obeh dojk skupaj za vsaj 50 % v primerjavi z izhodiščem od 1. dne in po 6 mesecih študije, prenašanje zdravila in varnost.
The small change in the rate of absorption is not expected to result in a clinically significant effect on steady-state plasma concentrations during once daily dosing of Arimidex tablets. 
Ni pričakovati, da bi majhna sprememba hitrosti absorpcije klinično pomembno vplivala na plazemsko koncentracijo v stanju dinamičnega ravnovesja med uporabo tablet zdravila Arimidex enkrat na dan.
• Raised or high levels of a fatty substance known as cholesterol in your blood. 
• zvišanje koncentracije maščobe, imenovane holesterol, v krvi.
• Pregnant or breast-feeding women. 
• nosečnicah in doječih ženskah.
For the primary endpoints, Study 1033IL/0030 showed that Arimidex had a statistically significant advantage over tamoxifen for time to tumour progression (Hazard ratio (HR) 1.42, 95% Confidence Interval (CI) [1.11, 1.82], Median time to progression 11.1 and 5.6 months for Arimidex and tamoxifen respectively, p=0.006); objective tumour response rates were similar for Arimidex and tamoxifen. 
Kar zadeva primarne opazovane dogodke, je študija 1033IL/0030 pokazala, da je imelo zdravilo Arimidex statistično značilno prednost pred tamoksifenom za čas do napredovanja tumorja (razmerje ogroženosti (HR) 1,42, 95% interval zaupanja (IZ) [1,11, 1,82], mediana časa do napredovanja 11,1 in 5,6 mesecev za Arimidex in tamoksifen, (p = 0,006); objektivni delež odziva tumorja je bil pri zdravilu Arimidex in tamoksifenu podoben.
In both studies there were no significant differences between treatment arms with respect to any of the efficacy parameters. 
V nobeni študiji ni bilo značilnih razlik med terapevtskima krakoma, kar zadeva katerikoli parameter učinkovitosti.
Cimetidine, a weak, unspecific inhibitor of CYP enzymes, did not affect the plasma concentrations of anastrozole. 
Cimetidin, ki je šibek in nespecifičen zaviralec encimov CYP, ni vplival na koncentracijo anastrozola v plazmi.
The primary endpoints for both trials were time to tumour progression, objective tumour response rate, and safety. 
V obeh preskušanjih so bili primarni opazovani dogodki čas do napredovanja tumorja, objektivni delež odziva tumorja in varnost.
- It does not matter if you take Arimidex before, with or after food. 
- Ni pomembno, ali zdravilo Arimidex vzamete pred jedjo, med jedjo ali po jedi.
Do not take Arimidex if any of the above apply to you. 
Ne vzemite zdravila Arimidex, če kaj od naštetega velja za vas.
p-value Time to distant recurrenced 
vrednost p Čas do oddaljene ponovitved
The apparent clearance (CL/F) of anastrozole, following oral administration, was approximately 30% lower in volunteers with stable hepatic cirrhosis than in matched controls (Study 1033IL/0014). 
Navidezni očistek (CL/F) anastrozola je bil po peroralni uporabi približno 30 % manjši pri prostovoljcih s stabilno cirozo jeter kot pri ujemajočih se kontrolnih osebah (študija 1033IL/0014).
No statistically significant difference from placebo was observed for the growth related parameters of predicted adult height, height, height SDS (standard deviation score), and height velocity. 
V primerjavi s placebom niso ugotovili statistično pomembne razlike v rastnih parametrih predvidene odrasle višine, višine, standardnih odklonov višine (vrednosti po standardnih odklonih) in hitrosti rasti.
Myocardial infarct 
Miokardni infarkt
In animal studies, anastrozole demonstrated low acute toxicity. 
V študijah na živalih je bila akutna toksičnost anastrozola majhna.
Effects on your bones 
Učinki na kosti
Like all medicines, Arimidex can cause side effects, although not everybody gets them. 
Kot vsa zdravila ima lahko tudi zdravilo Arimidex neželene učinke, ki pa se ne pojavijo pri vseh bolnikih.
A total of 1,021 patients were randomised to receive 1 mg of Arimidex once daily or 20 mg of tamoxifen once daily. 
Skupaj 1.021 bolnic so randomizirali na zdravljenje z 1 mg zdravila Arimidex enkrat na dan ali 20 mg tamoksifena enkrat na dan.
The most frequently reported adverse reactions were headache, hot flushes, nausea, rash, arthralgia, joint stiffness, arthritis, and asthenia. 
Najpogosteje opisani neželeni učinki so bili glavobol, valovi vročine, navzea, izpuščaj, artralgija, togost sklepov, artritis in astenija.
• Inflammation of the small blood vessels causing red or purple colouring of the skin. 
• vnetje drobnih žil, ki povzroči rdeče ali škrlatno obarvanje kože.
Fractures of the spine, hip, or wrist/Colles Wrist/Colles fractures 
Zlomi hrbtenice, kolka ali zapestja/Collesovi zlomi Zlomi zapestja/Collesovi zlomi Zlomi hrbtenice
Each film-coated tablet contains 1 mg of anastrozole. 
Ena filmsko obložena tableta vsebuje 1 mg anastrozola.
Patients in the low risk group received Arimidex alone (N=42), those in the moderate group were randomised to Arimidex plus risedronate 35 mg once a week (N=77) or Arimidex plus placebo (N=77) and those in the high risk group received Arimidex plus risedronate 35 mg once a week (N=38). 
Bolnice v skupini z majhnim tveganjem so dobile samo zdravilo Arimidex (n = 42), bolnice v skupini z zmernim tveganjem so randomizirali na zdravilo Arimidex in risedronat 35 mg enkrat na teden (n = 77) ali na zdravilo Arimidex in placebo (n = 77), bolnice v skupini z velikim tveganjem pa so dobile zdravilo Arimidex in risedronat 35 mg enkrat na teden (n = 38).
- If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. 
- Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
A two-year mouse oncogenicity study resulted in the induction of benign ovarian tumours and a disturbance in the incidence of lymphoreticular neoplasms (fewer histiocytic sarcomas in females and more deaths as a result of lymphomas). 
Dveletna študija onkogenosti na miših je povzročila indukcijo benignih tumorjev jajčnika in motnje v incidenci limforetikularnih novotvorb (manj histiocitnih sarkomov pri ženskah in več smrti zaradi limfomov).
Table 2 ATAC study pre-specified adverse events Adverse events 
Preglednica 2 Vnaprej opredeljeni neželeni učinki v študiji ATAC Neželeni učinki
Arimidex is not recommended for use in children and adolescents as safety and efficacy have not been established in this group of patients (see section 5.1). 
Zdravila Arimidex ni priporočljivo uporabljati pri otrocih in mladostnikih, ker njegova varnost in učinkovitost v tej skupini bolnikov nista ugotovljeni (glejte poglavje 5.1).
Clinical trials have been conducted with various dosages of Arimidex, up to 60 mg in a single dose given to healthy male volunteers and up to 10 mg daily given to postmenopausal women with advanced breast cancer; these dosages were well tolerated. 
Klinična preskušanja so bila opravljena z različnimi odmerjanji zdravila Arimidex do 60 mg v enkratnem odmerku, uporabljenem pri zdravih moških prostovoljcih, in do 10 mg na dan pri ženskah po menopavzi z napredovalim rakom dojke; preiskovane osebe so ta odmerjanja dobro prenesle.
The table below presents the frequency of pre-specified adverse events in the ATAC study after a median follow-up of 68 months, irrespective of causality, reported in patients receiving trial therapy and up to 14 days after cessation of trial therapy. 
Spodnja preglednica prikazuje pogostnost vnaprej opredeljenih neželenih učinkov v študiji ATAC po mediano 68-mesečnem spremljanju (ne glede na vzročnost), zabeleženih pri osebah, ki so prejemale raziskovano zdravilo in do 14 dni po prenehanju njegove uporabe.
Reducing circulating estradiol levels has been shown to produce a beneficial effect in women with breast cancer. 
Zmanjšanje koncentracije estradiola v obtoku ima pri ženskah z rakom dojke dokazano ugoden vpliv.
There were no clinically significant interactions with bisphosphonates (see section 5.1). 
Klinično pomembnih medsebojnih delovanj z difosfonati ni bilo (glejte poglavje 5.1).
• Changes in blood tests that show how well your liver is working. 
• spremembe izvidov preiskav krvi, ki kažejo delovanje jeter
A single dose of Arimidex that results in life-threatening symptoms has not been established. 
Posamičen odmerek zdravila Arimidex, ki bi povzročil življensko nevarne simptome, ni ugotovljen.
In an oral acute toxicity study in the dog, the median lethal dose was greater than 45 mg/kg/day. 
V študiji akutne peroralne toksičnosti na psih je bil mediani smrtni odmerek večji od 45 mg/kg/dan.
Unless specified, the frequency categories were calculated from the number of adverse events reported in a large phase III study conducted in 9,366 postmenopausal women with operable breast cancer given adjuvant treatment for five years (the Arimidex, Tamoxifen, Alone or in Combination [ATAC] study). 
Če ni navedeno drugače, so bile kategorije pogostnosti izračunane na podlagi števila neželenih učinkov, zabeleženih v veliki študiji III. faze, ki je zajela 9.366 žensk po menopavzi, ki so imele operabilnega raka dojke in so pet let prejemale adjuvantno zdravljene (študija ATAC [Arimidex, Tamoxifen, Alone or in Combination]).
Gynaecomastia studies 
Študije ginekomastije
In animal studies adverse effects were only seen at high doses. 
V študijah na živalih so neželene učinke opažali le pri velikih odmerkih.
Arimidex is not indicated for use in children and adolescents. 
Zdravilo Arimidex ni indicirano za uporabo pri otrocih in mladostnikih.
If you forget to take Arimidex 
Če ste pozabili vzeti zdravilo Arimidex
The Arimidex safety profile in these 3 studies was consistent with the known safety profile established in postmenopausal women with hormone receptor-positive early breast cancer. 
Varnostne značilnosti zdravila Arimidex v teh 3 študijah so se skladale z znanimi varnostnimi značilnostmi, ugotovljenimi pri ženskah po menopavzi, ki so imele zgodnjega raka dojke s pozitivnimi hormonskimi receptorji.
Arimidex is indicated for the: 
Zdravilo Arimidex je indicirano za:
- The active substance is anastrozole. 
- Zdravilna učinkovina je anastrozol.
What Arimidex looks like and contents of the pack 
Izgled zdravila Arimidex in vsebina pakiranja
These changes are considered to be mouse-specific effects of aromatase inhibition and not clinically relevant to the treatment of patients with anastrozole. 
Te spremembe veljajo za učinke zavrtja aromataze, ki so specifični za miši, in ne veljajo za klinično pomembne pri zdravljenju bolnikov z anastrozolom.
Before treatment with Arimidex check with your doctor or pharmacist - if you still have menstrual periods and have not yet gone through the menopause. 
Bodite posebno pozorni pri uporabi zdravila Arimidex Pred zdravljenjem z zdravilom Arimidex se posvetujte z zdravnikom ali s farmacevtom - če še imate menstruacije in še niste imeli menopavze.